Kimikazu Matsumoto

Kimikazu Matsumoto

Auto-generated profile, based on publicly available information

Kimikazu Matsumoto

Children's Cancer Center, National Center for Child Health and Development, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2019 in Cancers
Verified
Journal Article
Open access
PDF file
YYYohei Yamada
Yohei Yamada
MOMichinobu Ohno
Michinobu Ohno
AFAkihiro Fujino
Akihiro Fujino
YKYutaka Kanamori
Yutaka Kanamori
RIRie Irie
Rie Irie
THTomoro Hishiki
Tomoro Hishiki
Fluorescence-guided surgery with indocyanine green (ICG) for malignant hepatic tumors has been gaining more attention with technical advancements. Since hepatoblastomas (HBs) possess similar features to hepatocellular carcinoma, fluorescence-guided surgery can be used for HBs, as aggressive surgical resection, even for distant metastases of HBs, often contributes positively to R0 (complete) resection and subsequent patient survival. Despite a few caveats, fluorescence-guided surgery allows for the more sensitive identification of lesions that may go undetected by conventional imaging or be invisible macroscopically. This leads to precise resection of distant metastatic tumors as well as primary liver tumors.

26 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
AMAtsushi Makimoto
Atsushi Makimoto
HFHiroyuki Fujisaki
Hiroyuki Fujisaki
KMKimikazu Matsumoto
Kimikazu Matsumoto
YTYoshiyuki Takahashi
Yoshiyuki Takahashi
YCYuko Cho
Yuko Cho
TITomoko Iehara
Tomoko Iehara
Retinoids are vitamin A derivatives and include trans-retinoic acid, isotretinoin, tamibarotene, and bexarotene, all of which are currently available for clinical use. The clinical development of retinoid therapy for neuroblastoma has a history spanning more than four decades. The most promising agent is isotretinoin, which can contribute to improving event-free survival in patients with high-risk neuroblastoma by approximately 10% when administered over six months as maintenance therapy. Although isotretinoin is regarded as an essential component in the standard clinical management of high-risk neuroblastoma, its use for this purpose in the US and EU is off-label. To promote isotretinoin use in Japan as a treatment for neuroblastoma, our clinical research team is planning to launch an investigator-initiated, registration-directed clinical trial. The present review article discusses the basic science behind retinoid therapy, pre-clinical/clinical evidence on neuroblastoma, the concept of the proposed clinical trial, and prospects for this therapy.

18 July 2012 in Journal of Medical Virology
Verified
Journal Article
Closed access
PDF file
MIMasaru Ihira
Masaru Ihira
YEYoshihiko Enomoto
Yoshihiko Enomoto
YKYoshiki Kawamura
Yoshiki Kawamura
HNHidetaka Nakai
Hidetaka Nakai
KSKen Sugata
Ken Sugata
TYTetsushi Yoshikawa
Tetsushi Yoshikawa

22 January 2018 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
TOTomoo Osumi
Tomoo Osumi
STShin‐Ichi Tsujimoto
Shin‐Ichi Tsujimoto
KNKazuhiko Nakabayashi
Kazuhiko Nakabayashi
MTMaki Taniguchi
Maki Taniguchi
RSRyota Shirai
Ryota Shirai
MKMotohiro Kato
Motohiro Kato

20 November 2018 in Molecular Genetics and Metabolism Reports
Verified
Journal Article
Open access
PDF file
KKKoji Kato
Koji Kato
RMRyo Maemura
Ryo Maemura
MWManabu Wakamatsu
Manabu Wakamatsu
AYAyako Yamamori
Ayako Yamamori
MHMotoharu Hamada
Motoharu Hamada
NYNao Yoshida
Nao Yoshida
Objective: The prognosis of adrenoleukodystrophy (ALD)with neurological involvement is generally dismal; however, allogeneic stem cell transplantation (SCT) is recognized as effective to stabilize or improve the clinical symptoms of ALD. Herein, we report the clinical outcomes of patients with ALD who consecutively underwent allogeneic stem cell transplantation with reduced intensity conditioning at our institution. Patients: Sixteen patients with ALD, who were symptomatic (n = 14) or presymptomatic (n = 2), received SCT from 2010 to 2016. The stem cell source was cord blood (n = 14), or bone marrow from a human leukocyte antigen identical sibling (n = 2). The conditioning regimen prior to transplantation was reduced intensity and consisted of fludarabine (125 mg/m2), melphalan (140 mg/m2) and low dose total body irradiation (TBI) of 4Gy (n = 15) or 3Gy (n = 1). Results: Primary engraftment was obtained in 11 patients, and 4 of the 5 patients who lost the primary graft received a second cord blood transplantation and were engrafted. Five years overall and event-free survival were 90.9% and 61.1% respectively, with a median of 45 months (range 16–91). Loes score stabilized or improved by 18 months after transplantation except for patients with internal capsule involvement. Conclusion: Allogeneic SCT with reduced intensity conditioning for patients with ALD was safely performed without major transplant-related complications even in symptomatic patients and neurological symptoms were stabilized after SCT in patients without internal capsule involvement.

16 July 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
NHNobuyuki Hyakuna
Nobuyuki Hyakuna
YHYoshiko Hashii
Yoshiko Hashii
HIHiroyuki Ishida
Hiroyuki Ishida
KUKatsutsugu Umeda
Katsutsugu Umeda
YTYoshiyuki Takahashi
Yoshiyuki Takahashi
KKKoji Kato
Koji Kato